CoChat
Sign Up
Cited by 316

Cell-to-cell communication: microRNAs as hormones.

Bayraktar, Recep, Van Roosbroeck, Katrien, Calin, George A.·2017·Molecular Oncology
DOI 10.1002/1878-0261.12144PMC PMC5709614
Open this paper in CoChat — free account

Abstract

Mammalian cells can release different types of extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies. Accumulating evidence suggests that EVs play a role in cell‐to‐cell communication within the tumor microenvironment. EVs’ components, such as proteins, noncoding RNAs [microRNAs (miRNAs), and long noncoding RNAs (lncRNAs)], messenger RNAs (mRNAs), DNA, and lipids, can mediate paracrine signaling in the tumor microenvironment. Recently, miRNAs encapsulated in secreted EVs have been identified in the extracellular space. Mature miRNAs that participate in intercellular communication are released from most cells, often within EVs, and disseminate through the extracellular fluid to reach remote target cells, including tumor cells, whose phenotypes they can influence by regulating mRNA and protein expression either as tumor suppressors or as oncogenes, depending on their targets. In this review, we discuss the roles of miRNAs in intercellular communication, the biological function of extracellular miRNAs, and their potential applications for diagnosis and therapeutics. We will give examples of miRNAs that behave as hormones.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/1878-0261.12144

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 102

  1. Al‐Khalaf HH and Aboussekhra A (2017) p16INK4A induces senescence and inhibits EMT through microRNA‐141/microRNA‐146b‐5p‐dependent repression of AUF1. Mol Carcinog 56, 985– 999. 27596953
  2. Ambros V (2004) The functions of animal microRNAs. Nature 431, 350– 355. 15372042
  3. Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, Stephens R, Maxwell GL, Jazaeri A, Risinger JI et al (2013) Silencing of miR‐148a in cancer‐associated fibroblasts results in WNT10B‐mediated stimulation of tumor cell motility. Oncogene 32, 3246– 3253. 22890324 PMC3711253
  4. Arita S, Baba E, Shibata Y, Niiro H, Shimoda S, Isobe T, Kusaba H, Nakano S and Harada M (2008) B cell activation regulates exosomal HLA production. Eur J Immunol 38, 1423– 1434. 18425730
  5. Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK et al (2016) Exosomal transfer of stroma‐derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun 7, 11150. 27021436 PMC4820618
  6. Baer C, Squadrito ML, Laoui D, Thompson D, Hansen SK, Kiialainen A, Hoves S, Ries CH, Ooi CH and De Palma M (2016) Suppression of microRNA activity amplifies IFN‐gamma‐induced macrophage activation and promotes anti‐tumour immunity. Nat Cell Biol 18, 790– 802. 27295554
  7. Baroni S, Romero‐Cordoba S, Plantamura I, Dugo M, D'Ippolito E, Cataldo A, Cosentino G, Angeloni V, Rossini A, Daidone MG et al (2016) Exosome‐mediated delivery of miR‐9 induces cancer‐associated fibroblast‐like properties in human breast fibroblasts. Cell Death Dis 7, e2312. 27468688 PMC4973361
  8. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281– 297. 14744438
  9. Batool M, Anwar MA and Choi S (2016) Toll‐like receptors targeting technology for the treatment of lymphoma. Expert Opin Drug Discov 11, 1047– 1059. 27602749
  10. Bayraktar R, Pichler M, Kanlikilicer P, Ivan C, Bayraktar E, Kahraman N, Aslan B, Oguztuzun S, Ulasli M, Arslan A et al (2017) MicroRNA 603 acts as a tumor suppressor and inhibits triple‐negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget 8, 11641– 11658. 28036267 PMC5355293
  11. Berindan‐Neagoe I and Calin GA (2014) Molecular pathways: microRNAs, cancer cells, and microenvironment. Clin Cancer Res 20, 6247– 6253. 25512634 PMC4461223
  12. Berindan‐Neagoe I, Monroig Pdel C, Pasculli B and Calin GA (2014) MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin 64, 311– 336. 25104502 PMC4461198
  13. Binnemars‐Postma K, Storm G and Prakash J (2017) Nanomedicine strategies to target tumor‐associated macrophages. Int J Mol Sci 18, 979. PMC5454892 28471401
  14. Biswas SK and Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11, 889– 896. 20856220
  15. Boon RA and Vickers KC (2013) Intercellular transport of microRNAs. Arterioscler Thromb Vasc Biol 33, 186– 192. 23325475 PMC3580056
  16. Bullrich F, Fujii H, Calin G, Mabuchi H, Negrini M, Pekarsky Y, Rassenti L, Alder H, Reed JC, Keating MJ et al (2001) Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Can Res 61, 6640– 6648. 11559527
  17. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K et al (2002) Frequent deletions and down‐regulation of micro‐ RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99, 15524– 15529. 12434020 PMC137750
  18. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18, 997– 1006. 18766170
  19. Chen M, Calin GA and Meng QH (2014a) Circulating microRNAs as promising tumor biomarkers. Adv Clin Chem 67, 189– 214. 25735862
  20. Chen W, Wang H, Chen H, Liu S, Lu H, Kong D, Huang X, Kong Q and Lu Z (2014b) Clinical significance and detection of microRNA‐21 in serum of patients with diffuse large B‐cell lymphoma in Chinese population. Eur J Haematol 92, 407– 412. 24400911
  21. Chen X, Ying X, Wang X, Wu X, Zhu Q and Wang X (2017) Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA‐940 to induce macrophage M2 polarization. Oncol Rep 38, 522– 528. 28586039
  22. Cheng G (2015) Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev 81, 75– 93. 25220354
  23. Clayton A, Turkes A, Dewitt S, Steadman R, Mason MD and Hallett MB (2004) Adhesion and signaling by B cell‐derived exosomes: the role of integrins. FASEB J 18, 977– 979. 15059973
  24. Cocucci E and Meldolesi J (2011) Ectosomes. Curr Biol 21, R940– R941. 22153157
  25. Colombo M, Moita C, van Niel G, Kowal J, Vigneron J, Benaroch P, Manel N, Moita LF, Thery C and Raposo G (2013) Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci 126, 5553– 5565. 24105262
  26. Doldi V, Callari M, Giannoni E, D'Aiuto F, Maffezzini M, Valdagni R, Chiarugi P, Gandellini P and Zaffaroni N (2015) Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin‐6 in fibroblast activation. Oncotarget 6, 31441– 31460. 26375444 PMC4741617
  27. Donahue TR, Nguyen AH, Moughan J, Li L, Tatishchev S, Toste P and Farrell JJ (2014) Stromal microRNA‐21 levels predict response to 5‐fluorouracil in patients with pancreatic cancer. J Surg Oncol 110, 952– 959. 25132574 PMC4232442
  28. Donnarumma E, Fiore D, Nappa M, Roscigno G, Adamo A, Iaboni M, Russo V, Affinito A, Puoti I, Quintavalle C et al (2017) Cancer‐associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Oncotarget 8, 19592– 19608. 28121625 PMC5386708
  29. Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia‐Manero G and Calin GA (2008) MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia 22, 1095– 1105. 18323801
  30. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ et al (2012) MicroRNAs bind to toll‐like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA 109, E2110– E2116. 22753494 PMC3412003
  31. Fathullahzadeh S, Mirzaei H, Honardoost MA, Sahebkar A and Salehi M (2016) Circulating microRNA‐192 as a diagnostic biomarker in human chronic lymphocytic leukemia. Cancer Gene Ther 23, 327– 332. 27659777
  32. Fayyad‐Kazan H, Bitar N, Najar M, Lewalle P, Fayyad‐Kazan M, Badran R, Hamade E, Daher A, Hussein N, ElDirani R et al (2013) Circulating miR‐150 and miR‐342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med 11, 31. 23391324 PMC3579719
  33. Fernandez‐Mercado M, Manterola L, Larrea E, Goicoechea I, Arestin M, Armesto M, Otaegui D and Lawrie CH (2015) The circulating transcriptome as a source of non‐invasive cancer biomarkers: concepts and controversies of non‐coding and coding RNA in body fluids. J Cell Mol Med 19, 2307– 2323. 26119132 PMC4594673
  34. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ et al (2013) Prognostic value of miR‐155 in individuals with monoclonal B‐cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood 122, 1891– 1899. 23821659 PMC3779381
  35. Filip AA, Grenda A, Popek S, Koczkodaj D, Michalak‐Wojnowska M, Budzynski M, Wasik‐Szczepanek E, Zmorzynski S, Karczmarczyk A and Giannopoulos K (2017) Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL‐another piece in the puzzle. Ann Hematol 96, 33– 50. 27730344 PMC5203831
  36. Friedl P and Alexander S (2011) Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147, 992– 1009. 22118458
  37. Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC and Ding WQ (2016) Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res 18, 90. 27608715 PMC5016889
  38. He M, Xu Z, Ding T, Kuang DM and Zheng L (2009) MicroRNA‐155 regulates inflammatory cytokine production in tumor‐associated macrophages via targeting C/EBPbeta. Cell Mol Immunol 6, 343– 352. 19887047 PMC4003217
  39. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H and Bauer S (2004) Species‐specific recognition of single‐stranded RNA via toll‐like receptor 7 and 8. Science 303, 1526– 1529. 14976262
  40. Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, Choi YJ, Sweeney KE, Suski JM, Yin H et al (2017) Cell‐cycle‐targeting microRNAs as therapeutic tools against refractory cancers. Cancer Cell 31, 576– 590 e578. 28399412 PMC5425285
  41. Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q et al (2015) Stromal fibroblast‐derived miR‐409 promotes epithelial‐to‐mesenchymal transition and prostate tumorigenesis. Oncogene 34, 2690– 2699. 25065597
  42. Kadera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW and Donahue TR (2013) MicroRNA‐21 in pancreatic ductal adenocarcinoma tumor‐associated fibroblasts promotes metastasis. PLoS ONE 8, e71978. 23991015 PMC3750050
  43. Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16, 582– 598. 27550820
  44. Kalluri R and Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6, 392– 401. 16572188
  45. Kanada M, Bachmann MH, Hardy JW, Frimannson DO, Bronsart L, Wang A, Sylvester MD, Schmidt TL, Kaspar RL, Butte MJ et al (2015) Differential fates of biomolecules delivered to target cells via extracellular vesicles. Proc Natl Acad Sci USA 112, E1433– E1442. 25713383 PMC4378439
  46. Kanlikilicer P, Rashed MH, Bayraktar R, Mitra R, Ivan C, Aslan B, Zhang X, Filant J, Silva AM, Rodriguez‐Aguayo C et al (2016) Ubiquitous release of exosomal tumor suppressor miR‐6126 from ovarian cancer cells. Can Res 76, 7194– 7207. PMC5901763 27742688
  47. Larrea E, Sole C, Manterola L, Goicoechea I, Armesto M, Arestin M, Caffarel MM, Araujo AM, Araiz M, Fernandez‐Mercado M et al (2016) New concepts in cancer biomarkers: circulating miRNAs in liquid biopsies. Int J Mol Sci 17, 627. PMC4881453 27128908
  48. Lawrie CH (2013) MicroRNAs in hematological malignancies. Blood Rev 27, 143– 154. 23623930
  49. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS et al (2008) Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma. Br J Haematol 141, 672– 675. 18318758
  50. Lehmann SM, Kruger C, Park B, Derkow K, Rosenberger K, Baumgart J, Trimbuch T, Eom G, Hinz M, Kaul D et al (2012) An unconventional role for miRNA: let‐7 activates toll‐like receptor 7 and causes neurodegeneration. Nat Neurosci 15, 827– 835. 22610069
  51. Li X, Fan Q, Li J, Song J and Gu Y (2017) MiR‐124 down‐regulation is critical for cancer associated fibroblasts‐enhanced tumor growth of oral carcinoma. Exp Cell Res 351, 100– 108. 28077301
  52. Li Y, Zhao L, Shi B, Ma S, Xu Z, Ge Y, Liu Y, Zheng D and Shi J (2015) Functions of miR‐146a and miR‐222 in tumor‐associated macrophages in breast cancer. Sci Rep 5, 18648. 26689540 PMC4686897
  53. Ling H, Fabbri M and Calin GA (2013) MicroRNAs and other non‐coding RNAs as targets for anticancer drug development. Nat Rev Drug Discovery 12, 847– 865. 24172333 PMC4548803
  54. Liu X, Liu X, Wu Y, Wu Q, Wang Q, Yang Z and Li L (2017a) MicroRNAs in biofluids are novel tools for bladder cancer screening. Oncotarget 8, 32370– 32379. 28423688 PMC5458291
  55. Liu Y, Zhang J, Sun X, Su Q and You C (2017b) Down‐regulation of miR‐29b in carcinoma associated fibroblasts promotes cell growth and metastasis of breast cancer. Oncotarget 8, 39559– 39570. 28465475 PMC5503632
  56. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A and Flavell RA (2004) Recognition of single‐stranded RNA viruses by toll‐like receptor 7. Proc Natl Acad Sci USA 101, 5598– 5603. 15034168 PMC397437
  57. Mangala LS, Wang H, Jiang D, Wu SY, Somasunderam A, Volk DE, Lokesh GL, Li X, Pradeep S, Yang X et al (2016) Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight 1, e87754. 27777972 PMC5070952
  58. Mantovani A, Sica A and Locati M (2007) New vistas on macrophage differentiation and activation. Eur J Immunol 37, 14– 16. 17183610
  59. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova‐Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A et al (2008) Circulating microRNAs as stable blood‐based markers for cancer detection. Proc Natl Acad Sci USA 105, 10513– 10518. 18663219 PMC2492472
  60. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME and Lengyel E (2012) MicroRNAs reprogram normal fibroblasts into cancer‐associated fibroblasts in ovarian cancer. Cancer Discov 2, 1100– 1108. 23171795 PMC3685866
  61. Munker R and Calin GA (2011) MicroRNA profiling in cancer. Clin Sci 121, 141– 158. 21526983
  62. Nishimura M, Jung EJ, Shah MY, Lu C, Spizzo R, Shimizu M, Han HD, Ivan C, Rossi S, Zhang X et al (2013) Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov 3, 1302– 1315. 24002999 PMC3855315
  63. Nouraee N, Van Roosbroeck K, Vasei M, Semnani S, Samaei NM, Naghshvar F, Omidi AA, Calin GA and Mowla SJ (2013) Expression, tissue distribution and function of miR‐21 in esophageal squamous cell carcinoma. PLoS ONE 8, e73009. 24039846 PMC3769386
  64. Ortiz‐Quintero B (2016) Cell‐free microRNAs in blood and other body fluids, as cancer biomarkers. Cell Prolif 49, 281– 303. 27218664 PMC6496612
  65. Pang W, Su J, Wang Y, Feng H, Dai X, Yuan Y, Chen X and Yao W (2015) Pancreatic cancer‐secreted miR‐155 implicates in the conversion from normal fibroblasts to cancer‐associated fibroblasts. Cancer Sci 106, 1362– 1369. 26195069 PMC4638007
  66. Raposo G and Stoorvogel W (2013) Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 200, 373– 383. 23420871 PMC3575529
  67. Rashed MH, Kanlikilicer P, Rodriguez‐Aguayo C, Pichler M, Bayraktar R, Bayraktar E, Ivan C, Filant J, Silva A, Aslan B et al (2017) Exosomal miR‐940 maintains SRC‐mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget 8, 20145– 20164. 28423620 PMC5386751
  68. Redis RS, Calin S, Yang Y, You MJ and Calin GA (2012) Cell‐to‐cell miRNA transfer: from body homeostasis to therapy. Pharmacol Ther 136, 169– 174. 22903157 PMC3855335
  69. Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE and Hill R (2017) Cancer‐associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene 36, 1770– 1778. 27669441 PMC5366272
  70. Sansone P, Berishaj M, Rajasekhar VK, Ceccarelli C, Chang Q, Strillacci A, Savini C, Shapiro L, Bowman RL, Mastroleo C et al (2017) Evolution of cancer stem‐like cells in endocrine‐resistant metastatic breast cancers is mediated by stromal microvesicles. Can Res 77, 1927– 1941. PMC5392366 28202520
  71. Schoepp M, Strose AJ and Haier J (2017) Dysregulation of miRNA Expression in Cancer Associated Fibroblasts (CAFs) and its consequences on the tumor microenvironment. Cancers 9, 54. PMC5483873 28538690
  72. Shen Z, Qin X, Yan M, Li R, Chen G, Zhang J and Chen W (2017) Cancer‐associated fibroblasts promote cancer cell growth through a miR‐7‐RASSF2‐PAR‐4 axis in the tumor microenvironment. Oncotarget 8, 1290– 1303. 27901488 PMC5352055
  73. Shen H, Yu X, Yang F, Zhang Z, Shen J, Sun J, Choksi S, Jitkaew S and Shu Y (2016) Reprogramming of normal fibroblasts into cancer‐associated fibroblasts by miRNAs‐mediated CCL2/VEGFA signaling. PLoS Genet 12, e1006244. 27541266 PMC4991802
  74. Sica A, Schioppa T, Mantovani A and Allavena P (2006) Tumour‐associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti‐cancer therapy. Eur J Cancer 42, 717– 727. 16520032
  75. Sonda N, Simonato F, Peranzoni E, Cali B, Bortoluzzi S, Bisognin A, Wang E, Marincola FM, Naldini L, Gentner B et al (2013) miR‐142‐3p prevents macrophage differentiation during cancer‐induced myelopoiesis. Immunity 38, 1236– 1249. 23809164
  76. Squadrito ML, Pucci F, Magri L, Moi D, Gilfillan GD, Ranghetti A, Casazza A, Mazzone M, Lyle R, Naldini L et al (2012) miR‐511‐3p modulates genetic programs of tumor‐associated macrophages. Cell Rep 1, 141– 154. 22832163
  77. Staubach S, Razawi H and Hanisch FG (2009) Proteomics of MUC1‐containing lipid rafts from plasma membranes and exosomes of human breast carcinoma cells MCF‐7. Proteomics 9, 2820– 2835. 19415654
  78. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD et al (2010) Tumor‐associated macrophages and survival in classic Hodgkin's lymphoma. New Engl J Med 362, 875– 885. 20220182 PMC2897174
  79. Takeda K, Kaisho T and Akira S (2003) Toll‐like receptors. Annu Rev Immunol 21, 335– 376. 12524386
  80. Thery C, Ostrowski M and Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9, 581– 593. 19498381
  81. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille P, Brugger B and Simons M (2008) Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319, 1244– 1247. 18309083
  82. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ and Lotvall JO (2007) Exosome‐mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9, 654– 659. 17486113
  83. Van Roosbroeck K and Calin GA (2017) Cancer hallmarks and MicroRNAs: the therapeutic connection. Adv Cancer Res 135, 119– 149. 28882220
  84. Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez‐Aguayo C, Vannini I, Redis RS, D'Abundo L, Zhang X, Xiao L et al (2017) Combining anti‐Mir‐155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res 23, 2891– 2904. 27903673 PMC5449263
  85. Van Roosbroeck K, Pollet J and Calin GA (2013) miRNAs and long noncoding RNAs as biomarkers in human diseases. Exp Rev Mol Diagnost 13, 183– 204. 23477558
  86. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD and Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high‐density lipoproteins. Nat Cell Biol 13, 423– 433. 21423178 PMC3074610
  87. Vickers KC and Remaley AT (2012) Lipid‐based carriers of microRNAs and intercellular communication. Curr Opin Lipidol 23, 91– 97. 22418571 PMC5570485
  88. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK and Segal DM (2001) Regulation of toll‐like receptors in human monocytes and dendritic cells. J Immunol 166, 249– 255. 11123299
  89. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103, 2257– 2261. 16461460 PMC1413718
  90. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ and Wang K (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56, 1733– 1741. 20847327 PMC4846276
  91. Xu J, Cao Z, Liu W, You L, Zhou L, Wang C, Lou W, Sun B, Miao Y, Liu X et al (2016) Plasma miRNAs effectively distinguish patients with pancreatic cancer from controls: a multicenter study. Ann Surg 263, 1173– 1179. 26114496
  92. Yang J, Lu Y, Lin YY, Zheng ZY, Fang JH, He S and Zhuang SM (2016) Vascular mimicry formation is promoted by paracrine TGF‐beta and SDF1 of cancer‐associated fibroblasts and inhibited by miR‐101 in hepatocellular carcinoma. Cancer Lett 383, 18– 27. 27693460
  93. Yang TS, Yang XH, Chen X, Wang XD, Hua J, Zhou DL, Zhou B and Song ZS (2014) MicroRNA‐106b in cancer‐associated fibroblasts from gastric cancer promotes cell migration and invasion by targeting PTEN. FEBS Lett 588, 2162– 2169. 24842611
  94. Zhang WC, Chin TM, Yang H, Nga ME, Lunny DP, Lim EK, Sun LL, Pang YH, Leow YN, Malusay SR et al (2016) Tumour‐initiating cell‐specific miR‐1246 and miR‐1290 expression converge to promote non‐small cell lung cancer progression. Nat Commun 7, 11702. 27325363 PMC4919505
  95. Zhang Z, Li X, Sun W, Yue S, Yang J, Li J, Ma B, Wang J, Yang X, Pu M et al (2017) Loss of exosomal miR‐320a from cancer‐associated fibroblasts contributes to HCC proliferation and metastasis. Cancer Lett 397, 33– 42. 28288874
  96. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, Sun F, Lu J, Yin Y, Cai X et al (2010) Secreted monocytic miR‐150 enhances targeted endothelial cell migration. Mol Cell 39, 133– 144. 20603081
  97. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW and Wei YQ (2012) Prognostic significance of tumor‐associated macrophages in solid tumor: a meta‐analysis of the literature. PLoS ONE 7, e50946. 23284651 PMC3532403
  98. Zhang Y, Zhang D, Wang F, Xu D, Guo Y and Cui W (2015) Serum miRNAs panel (miR‐16‐2*, miR‐195, miR‐2861, miR‐497) as novel non‐invasive biomarkers for detection of cervical cancer. Sci Rep 5, 17942. 26656154 PMC4677300
  99. Zhao JL, Huang F, He F, Gao CC, Liang SQ, Ma PF, Dong GY, Han H and Qin HY (2016) Forced activation of Notch in macrophages represses tumor growth by upregulating miR‐125a and disabling tumor‐associated macrophages. Can Res 76, 1403– 1415. 26759236
  100. Zheng P, Chen L, Yuan X, Luo Q, Liu Y, Xie G, Ma Y and Shen L (2017) Exosomal transfer of tumor‐associated macrophage‐derived miR‐21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res 36, 53. 28407783 PMC5390430
  101. Zhong Y and Yi C (2016) MicroRNA‐720 suppresses M2 macrophage polarization by targeting GATA3. Biosci Rep 36, e00363. 27354564 PMC4974597
  102. Zhu W, Zhou K, Zha Y, Chen D, He J, Ma H, Liu X, Le H and Zhang Y (2016) Diagnostic value of serum miR‐182, miR‐183, miR‐210, and miR‐126 levels in patients with early‐stage non‐small cell lung cancer. PLoS ONE 11, e0153046. 27093275 PMC4836744

Cited by

Sorted by citations

Authors
Bayraktar, R., Van Roosbroeck, K., & Calin, G. A.
Affiliations
Department of Experimental Therapeutics The University of Texas MD Anderson Cancer Center Houston TX USA
Venue
Molecular Oncology
Publisher
Wiley
Published
2017-10-26
Volume
11
Issue
12
Pages
1673-1686
ISSN
  • 1574-7891
  • 1878-0261
DOI
10.1002/1878-0261.12144
PMC
PMC5709614
Cited by
316
References
10
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • NIH Clinical Center (UH3TR00943‐01)
  • Office of Strategic Coordination
  • Ladies Leukemia League
  • Lauri Strauss Leukemia Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review